Zydus Lifesciences on Tuesday said its US subsidiary Sentynl Therapeutics entered in agreement to buy Nasdaq listed BridgeBio Pharma's speciality asset Nulibry (fosdenopterin) used in treatment of rare genetic disorder that affects children. 

Under the terms of the agreement, Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing Zydus Lifesciences on Tuesday said its US subsidiary Sentynl Therapeutics entered in agreement to buy Nasdaq listed BridgeBio Pharma's speciality asset Nulibry (fosdenopterin) used in treatment of rare genetic disorder that affects children. Zydus didn't specify the financial details of the deal. Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing development and BridgeBio will share development responsibilities for fosdenopterin through approval of the marketing authorisation application already under accelerated assessment with the European Medicines Agency and through approval of its regulatory submission with the Israeli Ministry of Health. Sentynl will provide cash payments upon the achievement of certain regulatory milestones. BridgeBio will be eligible to receive commercial milestone payments as well as tiered royalties on adjusted net sales of Nulibry. Nulibry which is approved by USFDA is used for treatment of patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder that causes neurological damage. Zydus said Sentynl is also facilitating early diagnosis and treatment by enhancing awareness, new-born screening, genetic testing and patient support across multiple products and rare diseases including the development of a treatment for Menkes Disease, currently under rolling review by the USFDA, for which it partnered with Cyprium Therapeutics. “We are focused on our core purpose to empower patients suffering from rare disease with the freedom to live healthier and fulfilled lives," said Sharvil Patel, MD of Zydus.